Across 9 scored articles from Oct 16 to Nov 14, 2026 (UTC),
the average sentiment of BWX Technologies news is Somewhat Bullish (+48)
on a scale from −100 to +100.
That is up 10 points from the previous 30 days (+38).
💰Commercial operations sales jumped 72% to $302.5 million, highlighting a key growth engine.
🚀Management raised FY26 adjusted EPS guidance to $4.70–$4.80 per share from the prior range of $4.60–$4.75.
💵Free cash flow outlook was upgraded to $345–$360 million, reflecting improved financial flexibility.
Article
BWX Technologies (BWXT) reported solid third-quarter results, driven by significant growth in its commercial operations segment. Revenue increased 18% year-over-year to $901.6 million, with commercial sales surging 72% to $302.5 million. This strong performance reflects growing demand for the company's nuclear components and specialized services within both government defense and commercial power markets.
Following these results, management raised its full-year 2026 adjusted earnings per share (EPS) guidance to a range of $4.70–$4.80 per share, an increase from the previous forecast of $4.60–$4.75. Additionally, the company upgraded its free cash flow outlook to between $345 million and $360 million, signaling improved financial health and operational efficiency.
The positive momentum is attributed to the expanding manufacturing footprint supporting the commercial nuclear business. This guidance raise serves as a key bullish signal for investors, indicating that BWXT's core growth drivers remain robust despite broader market fluctuations.
Sector and industry come from company profile data. Sentiment is the AI score of the news articles on this page, averaged per day. Not investment advice.
BWX Technologies (BWXT) reported solid third-quarter results, driven by significant growth in its commercial operations segment. Revenue increased 18% year-over-year to $901.6 million, with commercial sales surging 72% to $302.5 million. This strong performance reflects growing demand for the company's nuclear components and specialized services within both government defense and commercial power markets.
Following these results, management raised its full-year 2026 adjusted earnings per share (EPS) guidance to a range of $4.70–$4.80 per share, an increase from the previous forecast of $4.60–$4.75. Additionally, the company upgraded its free cash flow outlook to between $345 million and $360 million, signaling improved financial health and operational efficiency.
The positive momentum is attributed to the expanding manufacturing footprint supporting the commercial nuclear business. This guidance raise serves as a key bullish signal for investors, indicating that BWXT's core growth drivers remain robust despite broader market fluctuations.
On November 2, 2026, BWX Technologies (NYSE:BWXT) reported third-quarter 2026 results showing 10% top-line growth to $953 million. Management raised the low end of its full-year free cash flow guidance and highlighted strong performance across both Government and Commercial Operations segments driven by rising global energy security needs.
The company's Government Operations segment achieved a 22.6% adjusted EBITDA margin as high-purity depleted uranium (HPDU) programs scaled up. CEO Rex Geveden announced the initiation of construction on a new large-scale facility in Jonesborough, Tennessee, to support a $1.6 billion contract for producing 300 metric tons of HPDU annually, expected to drive meaningful revenue growth through 2027.
In its Commercial Operations segment, BWXT posted 25% total revenue growth while expanding physical operations to handle surging nuclear power market demand. The company completed expansions at its Canadian and Cambridge facilities, increasing heavy component manufacturing capacity by approximately 50% to execute on a deep backlog associated with small modular reactors (SMRs) and other new awards.
Looking ahead, BWX Technologies expects high single-digit to low double-digit growth in Adjusted EBITDA and adjusted earnings per share for 2027. Management emphasizes that long-term value creation depends on converting opportunities into profitable growth and strong cash generation, underscoring confidence in the 2030 financial targets established at Investor Day.
📈 BWXT Q3 revenue hit $953M, up 10% year-over-year.
BWX Technologies (BWXT) reported third-quarter results showing a 10% increase in revenue to $953 million, though this figure missed Wall Street estimates of $971 million. Despite the top-line miss, the company delivered strong profitability with adjusted earnings per share rising 16% to $1.26, beating analyst expectations of $1.19. This performance was driven primarily by a significant 26% surge in operating income from its Government operations segment.
The positive financial momentum for BWXT is anchored by the successful selection of its nuclear reactor technology for the U.S. Army's Janus program. The company highlighted this specific contract win as a key driver of its recent results, signaling strong demand for its core defense capabilities. Management provided preliminary guidance suggesting that full-year 2027 revenue will grow in the high single digits, indicating confidence in sustained government spending on nuclear modernization.
In the broader market context, BWXT shares have faced selling pressure this year, falling approximately 30%, which contrasts with the bullish sentiment seen for peers like Curtiss-Wright. While the company navigates a challenging stock price environment and faces potential macroeconomic headwinds regarding defense budgets, its specific operational wins in nuclear technology provide a distinct positive outlook for future earnings growth.
📈 Q3 revenue hit $953M, up 10% YoY despite missing consensus.
💰 Adjusted EPS beat estimates at $1.26 vs $1.19 expectation.
🚀 Government operating income surged 26% on Janus program selection.
📅 FY2027 revenue guidance set for high single-digit growth.
📈 BWXT reported Q3 revenue of $953 million, representing a 10% year-over-year increase despite missing the consensus estimate of $971 million.
💰 The company beat analyst expectations for adjusted EPS with results of $1.26 compared to an estimated $1.19 per share.
🚀 Operating income from Government operations surged 26%, driven by the selection of nuclear reactor technology for the U.S. Army's Janus program.
📅 Management provided preliminary guidance expecting FY2027 revenue to grow in the high single digits.
📉 BWXT shares have declined approximately 30% year-to-date, reflecting broader market selling pressure on defense stocks despite recent operational wins.
🏛️ The company secured a significant contract win for its nuclear reactor technology, reinforcing its strategic position in Army modernization efforts.
Bullish Signals
Gov operating income surged 26% on Janus reactor selection.
Beat EPS estimates at $1.26 vs $1.19 consensus.
Risk Factors
Q3 revenue missed estimates at $953M vs $971M.
Stock fell ~30% despite operational improvements.
Bullish Signals
Operating income from Government operations surged 26%, driven by the successful selection of its nuclear reactor technology for the U.S. Army's Janus program.
The company beat Wall Street estimates for adjusted EPS, reporting $1.26 per share against a consensus expectation of $1.19.
Risk Factors
Q3 revenue of $953 million came in below the market estimate of $971 million, indicating a top-line miss despite earnings growth.
The stock has experienced significant selling pressure this year, falling approximately 30%, which contrasts with recent operational improvements.
BWX Technologies (NYSE: BWXT) is being evaluated as a potential buy following a significant sell-off in the nuclear energy sector, which has been impacted by rising AI electricity demand. While Oklo has fallen 86%, BWX Technologies has declined 45% but maintains a more established position with diversified revenue streams across military and commercial markets.
The company generates reliable revenue from long-term contracts building nuclear reactors for the U.S. Navy, which power aircraft carriers and submarines. Additionally, BWX is expanding its commercial footprint by selling components to the Canadian nuclear market and pursuing small modular reactor (SMR) projects with partners like GE Hitachi, resulting in a 25% year-over-year growth in commercial revenue.
In the third quarter, overall revenue increased 10% year over year to $953 million. The company is projected to generate approximately $350 million in free cash flow for the current year, implying a price-to-free-cash-flow ratio of 34x. Analysts view BWX as a superior investment compared to Oklo due to its immediate revenue generation and lower operational risk.
📈 BWXT down 45% from highs but holds $12B market cap buy opportunity.
🛡️ Secures reliable revenue via long-term U.S. Navy nuclear reactor contracts.
🌍 Achieved 25% YoY commercial growth selling components to Canadian nuclear market.
💰 Q3 revenue grew 10% YoY to reach $953 million consistently.
💵 Expected $350M free cash flow this year implying 34x P/FCF ratio.
📈 BWX Technologies is down 45% from highs while maintaining a $12 billion market cap, presenting a buy opportunity after the sector sell-off.
🛡️ The company secures reliable revenue through long-term contracts building nuclear reactors for the U.S. Navy to power aircraft carriers and submarines.
🌍 BWX has achieved 25% year-over-year growth in commercial revenue by selling components to the Canadian nuclear market and securing SMR contracts with GE Hitachi.
💰 Q3 overall revenue grew 10% year over year to reach $953 million, demonstrating consistent top-line performance.
💵 The company is expected to generate around $350 million in free cash flow this year, implying a P/FCF ratio of 34x.
🚀 BWX is developing futuristic nuclear technologies including space-based propulsion and microreactors for the U.S. government.
⚖️ Analysts favor BWX over Oklo because it offers diversified bets across the supply chain with steady military contracts and promising commercial opportunities.
Bullish Signals
Navy contracts provide reliable multi-decade revenue streams.
Risk Factors
Stock down 45% amid nuclear sector sell-off.
Commercial SMR growth remains distant.
Bullish Signals
The company generates reliable revenue from long-term contracts building nuclear reactors for the U.S. Navy, which span multiple decades.
Commercial revenue grew 25% year over year to $314 million driven by component sales in Canada and SMR contracts with GE Hitachi.
Overall revenue increased 10% year over year in the third quarter to reach $953 million.
The company is expected to generate around $350 million in free cash flow this year, implying a P/FCF ratio of 34x.
BWX Technologies is developing futuristic nuclear power technologies for the U.S., including space-based propulsion and microreactors.
Risk Factors
The stock has declined 45% from highs, reflecting a broader sell-off in the nuclear energy sector despite underlying business strength.
Commercial SMR segment is still in very early days, indicating that significant growth from this specific line of business is not immediate.
BWX Technologies (BWXT) reported third-quarter earnings of $1.26 per share, surpassing the Zacks Consensus Estimate of $1.19 and representing a 5.88% beat compared to the prior year's $1.00. This marks the fourth consecutive quarter where the company has exceeded consensus EPS estimates, demonstrating consistent profitability despite recent market volatility.
However, revenue for the quarter ended September 2026 came in at $952.97 million, missing the Zacks Consensus Estimate by 3.97%. This contrasts with the previous quarter where BWXT topped revenue expectations three times out of four, highlighting a divergence between earnings performance and top-line growth that will likely be scrutinized during management's commentary.
Despite beating earnings, BWX shares have underperformed the broader market, losing approximately 24.4% year-to-date versus the S&P 500's gain of 10.7%. The stock currently holds a Zacks Rank #3 (Hold) based on mixed estimate revisions ahead of the report, suggesting analysts expect near-term performance to track in line with the market as investors await further clarity on future guidance.
📈 BWXT Q3 EPS beat consensus by 5.88% at $1.26 per share.
💰 Company has beaten EPS estimates for four consecutive quarters.
📉 Revenue missed consensus by 3.97% at $952.97 million.
BWX Technologies has secured a multi-year framework agreement with Antares Nuclear to supply TRISO fuel made from HALEU for the microreactor fleet. The deal initially covers 1 MTU manufactured at BWX's Lynchburg, Virginia facility and ties long-lead manufacturing capacity directly to Antares' deployment schedule and future task orders specifying quantities and technical requirements.
The agreement reinforces BWX Technologies' role in advanced reactor fuel supply by qualifying its Lynchburg TRISO line for multiple advanced reactor programs. Analysts view this deal as a strategic step that deepens the company's involvement in commercial nuclear operations, though it represents a small portion of its roughly US$8.4 billion government-heavy backlog and does not immediately alter the near-term financial story.
The article projects BWX Technologies' revenue at US$4.8 billion and earnings at US$536.6 million by 2029, implying 10.7% yearly revenue growth and an earnings increase of about US$181 million from current levels. Key short-term factors for investors include execution on existing long-cycle contracts, cost control within Commercial Operations to maintain 2026 margins around 13%, and managing reliance on U.S. defense budgets alongside higher leverage.
While the TRISO deal strengthens the narrative of converting government backlog into steady commercial work, analysts warn that reinvestment in capacity must not erode profitability. The company's broader investment thesis relies on successfully translating framework deals into predictable task order volume without straining capital needs or widening project risk, particularly as Commercial Operations aims to become a meaningful complement to its defense franchise.
Jim Cramer addressed the recent 27% pullback in BWX Technologies (BWXT) stock during a Mad Money segment, attributing the decline to a weaker-than-expected August quarter rather than structural flaws. Despite the volatility, Cramer highlighted the company's bullish long-term targets for 2030 presented at its September 29 Investor Day, noting that most of the recent quarterly results were positive aside from one or two lines.
BWX Technologies maintains a virtual monopoly on manufacturing naval nuclear reactors and fuel components for the U.S. Navy, providing a sovereign defense moat with total backlog doubling to $8.4 billion. The company projects full-year 2026 revenue of $3.8 billion, with approximately 98% generated from core nuclear activities supporting Virginia-class submarines, Columbia-class ballistic missile submarines, and Gerald R. Ford-class aircraft carriers.
To capture accelerating global demand, BWXT is executing a strategic pivot by selling a majority stake in its non-core medical isotope unit for up to $800 million while retaining a 20% interest. Proceeds are being reallocated into high-return nuclear manufacturing assets, including a Precision Components Group acquisition and a 500,000-square-foot footprint expansion, supporting updated 2030 financial roadmap targets of $5.5 billion to $6 billion in annual revenue.
While the stock trades at around 36x TTM earnings, analysts note structural margin volatility in Government Operations and supply chain bottlenecks for military-grade alloys as primary headwinds. However, hedge fund holders expanded to 65 in the second quarter, with Alkeon Capital Management leading holdings, suggesting institutional confidence in BWXT's ability to balance sovereign defense obligations with high-margin nuclear infrastructure expansion.
📉 Stock down 27% over three months due to weaker-than-expected August quarter results.
🛡️ Holds virtual monopoly on naval nuclear reactors for Virginia and Columbia-class submarines.
💰 Projects $3.8B full-year 2026 revenue with 98% from core nuclear activities.
🔄 Selling majority of medical isotope unit for up to $800 million to fund growth.
📉 Jim Cramer notes a 27% stock pullback over three months driven by an August quarter that came in somewhat weaker than expected.
🛡️ BWXT holds a virtual monopoly on naval nuclear reactors, manufacturing propulsion systems for Virginia-class attack submarines and Columbia-class ballistic missile submarines.
📈 Total backlog doubled to $8.4 billion, representing roughly nine quarters of contracted run rate as of the September 29 Investor Day.
💰 The company projects full-year 2026 revenue of $3.8 billion, with approximately $3.7 billion (98%) generated directly from core nuclear activities.
🔄 BWXT is selling a majority stake in its non-core medical isotope unit for up to $800 million while retaining a 20% interest.
🏗️ Proceeds from the sale are being reallocated into high-return nuclear manufacturing assets, including a Precision Components Group acquisition.
🎯 Updated 2030 financial roadmap targets annual revenues of $5.5 billion to $6 billion on low double-digit compound organic growth.
💹 Adjusted EBITDA margins are projected to expand from 17.5% to approximately 20% by the end of the decade.
📉 The stock trades at around a 36x TTM price-to-earnings multiple and 27x forward earnings following the valuation reset.
⚠️ Margin volatility within Government Operations remains a constant, structural reality that frequently limits upside surprises.
🔧 Realizing margin expansion depends heavily on scaling unproven commercial SMR production lines while navigating supply chain bottlenecks.
📉 Insider selling has continued, including share sales by CEO Rex Geveden under a Rule 10b5-1 trading plan.
🏦 Hedge fund holders expanded to 65 in the second quarter compared to 61 in the preceding quarter according to Insider Monkey data.
📊 Alkeon Capital Management was the top hedge fund holder in Q2 with a position of 2.02 million shares.
📉 Short interest remains low at 4.42% of the public float as of the latest reporting period.
Bullish Signals
Holds naval nuclear reactor monopoly for U.S. Navy stability.
Risk Factors
Stock fell from $241 highs to $130-$140 range.
Government Operations margins face constant structural volatility.
SMR scaling depends on unproven lines and alloy bottlenecks.
CEO Rex Geveden sold shares via Rule 10b5-1.
Bullish Signals
BWX Technologies holds a virtual monopoly in manufacturing naval nuclear reactors and fuel components for the U.S. Navy, providing a sovereign defense moat that anchors long-term operational stability.
Total backlog doubled to $8.4 billion, representing roughly nine quarters of contracted run rate as highlighted at the September 29 Investor Day.
The company projects full-year 2026 revenue of $3.8 billion, with approximately $3.7 billion (98%) generated directly from core nuclear activities.
BWXT is selling a majority stake in its non-core medical isotope unit for up to $800 million while retaining a 20% interest to reallocate capital into high-return assets.
Proceeds are being invested in a Precision Components Group acquisition and a 500,000-square-foot footprint expansion to support nuclear manufacturing.
Updated 2030 financial roadmap targets annual revenues of $5.5 billion to $6 billion on low double-digit compound organic growth.
Adjusted EBITDA margins are projected to expand from 17.5% to approximately 20% by the end of the decade.
Second-quarter results reported non-GAAP diluted earnings per share of $1.07 on 18% revenue growth to $901.6 million.
Risk Factors
The stock has endured a severe pullback from its 52-week highs of over $241 down into the $130-$140 range, driven by a broader industrial selloff and a weaker-than-expected August quarter.
Margin volatility within Government Operations remains a constant, structural reality of defense contracting that frequently limits upside surprises.
Realizing projected margin expansion depends heavily on scaling unproven commercial SMR production lines while navigating ongoing supply chain bottlenecks for military-grade specialty alloys.
Insider selling has continued, including share sales by CEO Rex Geveden under a Rule 10b5-1 trading plan.
The article compares BWXT and OKLO as investment options in the nuclear sector, concluding that BWXT offers a stronger immediate investment case due to its established revenue streams and positive earnings. BWXT generates income through naval propulsion, commercial equipment sales, and services for advanced reactor developers like Antares, supported by an $8.4 billion backlog.
BWXT is positioned for expansion with recent acquisitions of Precision Components Group to boost U.S. manufacturing capacity and multiyear agreements for TRISO fuel production. Management projects free cash flow between $345 million and $360 million for 2026, providing the financial flexibility to fund growth without relying on the commercial viability of its own reactor designs.
In contrast, OKLO is viewed as a higher-risk play focused on owning and operating reactors, with significant hurdles remaining regarding construction, fuel supply, and regulatory approvals. While OKLO has secured a customer commitment from Meta for an Ohio campus and possesses substantial cash reserves, it faces expected losses in 2026 compared to BWXT's projected earnings growth.
Analysts favor BWXT over OKLO for investors seeking clearer near-term financial prospects and lower dependence on future milestones. BWXT carries a Zacks Rank of #3 (Hold), whereas OKLO holds a #4 (Sell) rating, reflecting the market's preference for BWXT's current profitability and diversified business model over OKLO's developmental stage.
📈 BWXT holds $8.4B backlog with orders 1.7x sales.
🏭 Precision Components acquisition boosts U.S. manufacturing capacity.
💰 Management forecasts $345M-$360M free cash flow for 2026.
Expansion spending may temporarily delay margin improvement.
Risks include higher costs or late deliveries.
Bullish Signals
The company holds an $8.4 billion backlog with orders exceeding sales by 1.7x, demonstrating robust demand for its equipment and services.
Management expects to generate between $345 million and $360 million in free cash flow for 2026, enabling organic growth and expansion.
The acquisition of Precision Components Group enhances U.S. manufacturing capacity and allows the company to internalize previously outsourced work.
A multiyear agreement with Antares provides a framework for TRISO fuel production, creating a diversified revenue stream from reactor developers.
BWXT's established operations in naval nuclear propulsion and commercial equipment provide a stable financial base compared to developmental peers.
The company outperformed OKLO by 22.4 percentage points over six months despite a broader market decline, showing relative resilience.
Risk Factors
Increased spending on facilities and workers to support expansion may temporarily hold back margin improvement before new capacity generates sufficient business.
The company retains the risk of higher operational costs or late deliveries despite its established customer base and backlog.
BWX Technologies (BWXT) announced that its BWXT Advanced Fuels subsidiary has secured a multi-year commercial agreement with Antares Nuclear to produce tri-structural isotropic (TRISO) nuclear fuel. This partnership establishes a framework for an initial allocation of 1 MTU, with provisions to scale production as Antares advances its reactor deployment program.
The fuel will be manufactured at BWXT's Lynchburg, Virginia facility using the same TRISO fabrication line currently utilized for the Department of War's Project Pele and Antares' Mark-0 reactors. This agreement strengthens BWXT's existing relationship with Antares, building upon earlier collaboration where BWXT-produced fuel supported Antares' recent Mark-0 criticality milestone.
The deal signifies a significant step in BWXT's progression from reactor demonstration phases to initial production deployments within the advanced nuclear sector. By leveraging its established fabrication capabilities for both military and commercial projects, BWXT is positioning itself as a key supplier for next-generation nuclear fuel technologies.
🤝 BWXT secures multi-year TRISO fuel deal with Antares Nuclear.
📦 Contract starts with 1 MTU allocation and scalable production options.
🏭 Fuel produced at Lynchburg facility using existing reactor lines.
🚀 Deal advances BWXT from demo phases to commercial deployment.
🔬 Agreement builds on successful Mark-0 criticality milestone partnership.
🤝 BWXT Advanced Fuels enters a multi-year commercial agreement with Antares Nuclear to produce TRISO nuclear fuel.
📦 The contract includes an initial allocation of 1 MTU with scalability options tied to Antares' evolving deployment requirements.
🏭 Production will occur at BWXT's Lynchburg, Virginia facility using the same line serving Project Pele and Mark-0 reactors.
🚀 This deal supports BWXT's transition from reactor demonstration phases to initial commercial production deployments.
🔬 The agreement leverages BWXT's existing successful relationship with Antares, following the recent Mark-0 criticality milestone.
Bullish Signals
Secures multi-year commercial TRISO fuel deal with Antares Nuclear.
Initial allocation 1 MTU for scalable advanced reactor support.
Production at Lynchburg facility shows operational readiness.
Builds on successful track record including Mark-0 criticality.
Bullish Signals
BWXT Advanced Fuels secures a multi-year commercial agreement with Antares Nuclear for TRISO fuel production.
The deal includes an initial allocation of 1 MTU with scalable terms to support Antares' advanced reactor program.
Production utilizes BWXT's Lynchburg facility and established TRISO fabrication line, demonstrating operational readiness.
The agreement builds on a successful track record, including supporting Antares' recent Mark-0 criticality milestone.
Jim Cramer recently issued contrasting investment verdicts on two nuclear and AI infrastructure plays, explicitly passing on BWXT while buying Nokia. The core of his decision rests on valuation multiples within a rising interest rate environment; he deemed BWXT's 30x forward P/E too expensive despite acknowledging the company is a 'great' business with strong fundamentals.
BWXT reported robust operational metrics in Q2, including an 18% revenue increase to $901.63 million and a backlog expansion of 40% year-over-year to $8.4 billion. However, Cramer's hesitation stems from the fact that much of the Small Modular Reactor (SMR) order flow remains years away from meaningful revenue recognition. In a tightening rate cycle, the analyst argues that investors cannot afford to own companies with persistent losses or those requiring long-term patience without immediate cash flow visibility.
The article contrasts BWXT's high valuation against its future-oriented nuclear thesis with Nokia's current performance driven by AI networking demand. While Cramer praised BWXT's quality, he maintained that the stock price already discounts the potential win, making it a 'pass' for now. The piece concludes that in a rate-tightening cycle, buyers prefer shorter time horizons and cash flow visible in the current fiscal year over long-duration stories requiring patience.
📉 Stock declined 15.37% YTD as nuclear premium gives back.
💰 Q2 revenue rose 18% to $901.63 million.
📦 Backlog surged 40% year-over-year to $8.4 billion.
📉 Q2 loss of $57.06M due to restructuring charges.
⏳ SMR revenue remains distant, creating current liability.
📉 Jim Cramer passed on BWXT due to a 30x forward P/E multiple deemed too expensive for a rising rate environment.
💰 BWXT reported Q2 revenue of $901.63 million, representing an 18% year-over-year increase.
📦 The company's backlog grew significantly to $8.4 billion, marking a 40% increase year-over-year.
⏳ A trailing twelve-month book-to-bill ratio of 1.7x indicates strong order intake relative to revenue.
🚀 SMR revenue remains years away from meaningful contribution, creating a liability in current market conditions.
📉 BWXT stock has declined 15.37% year-to-date as the nuclear renaissance premium gives back.
🏭 Cramer noted that today's price for BWXT already discounts the potential win of its nuclear exposure.
📉 The company recorded a $57.06 million loss in Q2 due to $445 million in accelerated restructuring charges.
📊 Free cash flow conversion is tracking at the low end of the 55% to 75% range.
🔍 BWXT trades at a trailing P/E of 38x, which Cramer considers too rich for the current discount rate.
Bullish Signals
Described as a 'great' and 'terrific' business with operational strength.
BWX Technologies (BWXT) shares have declined approximately 40% from their yearly highs, trading near $139 despite possessing a robust backlog of roughly $8.4 billion for U.S. Navy nuclear reactors. The company is the sole domestic manufacturer of these critical defense systems, holding a unique non-competitive position that ensures stable and predictable demand. Recent activity includes an $189 million contract award for naval nuclear fuel, reinforcing the strength of its core industrial business.
However, the stock's valuation remains elevated relative to current cash generation capabilities. While revenue has grown by 23% year-over-year, free cash flow contracted by roughly 12% to approximately $317 million. The market prices the equity at about 40 times trailing free cash flow, reflecting a bet on future expansion rather than immediate income. Capital expenditures are consuming significant liquidity as the company expands its manufacturing footprint in Ontario and converts its backlog into physical components.
Management has outlined a strategic plan to reach $550 million in annual free cash flow by 2030, targeting revenue near $6 billion and expanding EBITDA margins from 17.5% to 20%. To fund this industrial scaling, BWXT agreed to sell its medical-isotopes unit for up to $800 million while retaining a minority stake. The investment thesis relies entirely on the successful conversion of backlog into distributable cash over the next four years, as current yields remain low at roughly 2.5%.
📉 Shares fell 40% despite record $8.4B Navy reactor backlog.
💰 Free cash flow dropped 12% to $317M while revenue rose 23%.
🏭 Expanding Ontario plant 40% to support heavy nuclear manufacturing growth.
🎯 Targets $550M annual free cash flow by 2030 with $6B revenue.
⚓ Sole U.S. manufacturer of reactors for Navy submarines and carriers.
📉 BWXT shares fell 40% to $139, trading near a yearly low despite a record $8.4 billion Navy reactor backlog.
💰 The company generated only $317 million in free cash flow last year, down 12%, even as revenue rose 23%.
🏭 BWXT is expanding its Cambridge, Ontario plant by roughly 40% to support heavy nuclear manufacturing growth.
📜 Management guides revenue to $3.8 billion for the current year, with nearly all growth driven by nuclear contracts.
💸 The stock trades at approximately 40x trailing free cash flow and a yield of just 2.5%.
🔄 BWXT sold its medical-isotopes business for up to $800 million to fund reinvestment in reactor expansion.
🎯 The company targets $550 million in annual free cash flow by 2030 with revenue near $6 billion.
⚓ BWXT is the sole U.S. manufacturer of reactors for Navy submarines and aircraft carriers.
📈 A recent $189 million contract award for naval nuclear fuel was announced days before the article's publication.
🏛️ The company holds a modest net debt of about $1.4 billion against a market cap of roughly $12.7 billion.
Bullish Signals
Sole U.S. nuclear reactor manufacturer for Navy vessels.
Risk Factors
Free cash flow shrank 12% despite 23% revenue rise due to heavy capex.
Bullish Signals
BWX Technologies is the sole U.S. manufacturer of nuclear reactors for Navy submarines and aircraft carriers, securing non-competitive, multi-year demand.
The company secured an additional $189 million contract to manufacture naval nuclear fuel, reinforcing its stable backlog position.
Revenue is expected to grow significantly as the company converts its record backlog into distributable cash flow by 2030.
Management plans to expand EBITDA margins from approximately 17.5% this year to around 20% by 2030.
Risk Factors
Free cash flow shrank by roughly 12% last year despite a 23% increase in revenue due to heavy capital spending.
The stock trades at approximately 40 times trailing free cash flow, implying the market is pricing in future growth rather than current earnings power.
Current dividend yields are less than one percent, offering no income anchor while the company reinvests heavily in expansion.
Company updateContract renewalAI-generated analysis
BWX Technologies (BWXT) has experienced significant share price appreciation, returning 169.3% over the last five years, which has led to recent investor pressure regarding valuation. The company recently secured approximately $1.4 billion in new contracts and is increasing capital spending beyond its traditional Navy reactor business, aiming to reshape expectations for margins and future cash flows.
Analysts at Simply Wall St are evaluating BWXT's current share price of $143.83 against its intrinsic value using a Discounted Cash Flow (DCF) model. The analysis highlights that the company's latest twelve-month free cash flow stands at roughly $322 million, with projections assuming continued growth rather than stagnation. Consequently, the DCF model suggests the market is largely pricing in the company's current contract pipeline and investment needs.
Market sentiment regarding BWXT is currently divided between two distinct narratives. The 'bull case' argues that a record backlog of $6 billion, which represents a 70% year-over-year increase driven by multi-year defense contracts, indicates the stock is undervalued by 34%. Conversely, the 'bear case' contends that the market is paying a premium for growth technology with a P/E ratio around 50x, suggesting the stock is overvalued by 11%.
📈 BWXT delivered 169.3% total return to shareholders over five years.
💰 Secured $1.4 billion in new contracts outside Navy reactors.
🛡️ Boasts record $6 billion backlog, up 70% year-over-year.
📉 Bearish view: Stock is 11% overvalued due to high growth premiums.
🚀 Bullish view: Stock is 34% undervalued with expanding defense pipeline.
📈 BWXT has delivered a 169.3% total return to shareholders over the past five years.
💰 The company recently secured approximately $1.4 billion in new contracts outside of Navy reactors.
📊 BWXT currently trades at a P/E ratio of roughly 50x according to market narratives.
🛡️ The company boasts a record backlog of $6 billion, up 70% year-over-year.
💸 Latest twelve-month free cash flow for BWXT is estimated at approximately $322 million.
📉 A bearish narrative suggests the stock is 11% overvalued due to high growth premiums.
🚀 A bullish narrative claims the stock is 34% undervalued given its expanding defense pipeline.
🏭 BWXT is investing heavily in capital spending beyond its traditional nuclear reactor business.
Bullish Signals
Secured $1.4B in new contracts signaling strong demand.
Backlog hit record $6B, up 70% YoY.
Expanding pipeline with accelerating nuclear and medical demand.
BWX Technologies Inc. (NYSE: BWXT) shares surged approximately 8% on Tuesday following the announcement that its BANR microreactor technology was selected for a Transportable Nuclear Power Plant project in Belledune, New Brunswick. The facility, led by Prodigy Clean Energy and Indigenous partners Pabineau First Nation and Eel River Bar First Nations, will feature an up to 50 megawatt electric reactor with targeted in-service operation by the early 2030s.
The selected BWXT Advanced Nuclear Reactor is a high-temperature gas-cooled design producing 75 megawatts thermal using high-assay low-enriched uranium and TRISO fuel. The modular architecture allows for factory-built deployment with installation targeted at about 18 months, featuring passive cooling and flexible power conversion options suitable for commercial, industrial, and defense applications.
The Government of New Brunswick has provided a signed Letter of Intent to offtake the generated electricity, while BWXT Canada and its owned company Kinectrics Inc. will deploy a Canadian workforce to support the project. Principal fabrication of the two BANR units will occur at BWXT's facilities in Ontario, supported by established and new nuclear supply chain vendors as the companies move toward a definitive agreement for cooperative development.
📈 BWXT shares rose 8% after BANR microreactor selected for New Brunswick project.
⚛️ Facility hosts up to 50 MW electric Prodigy TNPP with factory-built deployment.
🤝 Government of New Brunswick signed Letter of Intent to offtake generated electricity.
🇨🇦 BWXT Canada and Kinectrics will deploy Canadian workforce for principal fabrication.
📈 BWX Technologies shares rose 8% after its BANR microreactor technology was selected for a Transportable Nuclear Power Plant project in Belledune, New Brunswick.
🏭 The facility will host an up to 50 megawatt electric Prodigy TNPP within the traditional territory of Pabineau and Eel River Bar First Nations.
⚛️ BWXT's Advanced Nuclear Reactor is a high-temperature gas-cooled design producing 75 megawatts thermal using high-assay low-enriched uranium in a TRISO fuel form.
🏗️ The modular infrastructure supports factory-built deployment with installation targeted at approximately 18 months for multi-decade lifecycle operations.
🤝 The Government of New Brunswick signed a Letter of Intent to offtake electricity generated by the project.
🇨🇦 BWXT Canada and Kinectrics Inc. will deploy a Canadian workforce to support the project with principal fabrication at BWXT's Ontario facilities.
🌍 BWXT and Prodigy are targeting commercial, industrial, and defense energy projects globally for future applications of BANR-TNPPs.
Bullish Signals
Shares rose 8% after reactor selection win in New Brunswick.
Bullish Signals
Shares rose 8% immediately following the announcement of a major reactor selection win in New Brunswick.
Secured a Letter of Intent from the Government of New Brunswick to offtake electricity generated by the new facility.
Demonstrated strong market confidence with its BANR microreactor technology being chosen for an Indigenous-led nuclear project.
Positioned for global expansion as it targets commercial, industrial, and defense energy projects beyond the initial Belledune deployment.
Jim Cramer highlighted a significant 27% pullback in BWX Technologies (NYSE:BWXT) stock over the past three months, attributing the decline to a weaker-than-expected Q2 report released on August 3rd. Despite the short-term volatility and broader industrial selloff driving prices down from 52-week highs above $241 to the $130-$140 range, Cramer views the situation as a temporary dislocation rather than a structural flaw in the company's business model.
At its September 29 Investor Day, BWX Technologies presented a robust long-term outlook anchored by its monopoly on U.S. Navy naval nuclear reactors for submarines and aircraft carriers. Management reported that total backlog has doubled to $8.4 billion, providing roughly nine quarters of contracted run rate visibility. For the fiscal year 2026, the company projects full-year revenue of $3.8 billion, with approximately 98% generated directly from core nuclear activities.
To capitalize on accelerating global demand in defense and commercial nuclear power, BWX Technologies is executing a strategic pivot to focus on high-return assets. The company plans to sell a majority stake in its non-core medical isotope unit for up to $800 million, with proceeds reallocated into manufacturing expansions, including a 500,000-square-foot footprint increase via the Precision Components Group acquisition. This strategy supports updated 2030 targets of annual revenues between $5.5 billion and $6 billion.
While the stock trades at a premium valuation of roughly 36x TTM earnings, reflecting high market expectations for commercial nuclear growth, analysts note specific headwinds including structural margin volatility in government operations and supply chain bottlenecks for military-grade alloys. However, hedge fund interest has expanded to 65 holders in Q2, with Alkeon Capital Management leading the pack, suggesting institutional confidence in the company's long-term compounder potential despite near-term valuation compression.
🛡️ Holds naval nuclear reactor monopoly securing sovereign defense moat.
📈 Backlog doubled to $8.4B; projects 2026 revenue of $3.8B.
💰 Selling medical unit for up to $800M to fund expansion.
⚠️ Margins face volatility from supply chain bottlenecks and scaling risks.
📉 BWX Technologies stock has dropped 27% over the past three months following a Q2 report that missed expectations, trading between $130 and $140 after peaking above $241.
🛡️ The company holds a virtual monopoly on manufacturing naval nuclear reactors for U.S. submarines and aircraft carriers, securing a sovereign defense moat.
📈 Total backlog has doubled to $8.4 billion, representing approximately nine quarters of contracted run rate for the core defense business.
💰 BWX Technologies projects 2026 full-year revenue of $3.8 billion, with roughly 98% derived directly from core nuclear activities.
🔄 The company is selling a majority stake in its non-core medical isotope unit for up to $800 million to fund high-return nuclear manufacturing assets.
🏗️ Proceeds from the sale will support a 500,000-square-foot footprint expansion through the Precision Components Group acquisition.
🎯 Updated 2030 financial targets include annual revenues of $5.5 billion to $6 billion with low double-digit compound organic growth.
💹 Adjusted EBITDA margins are expected to expand from 17.5% to approximately 20% by the end of the decade.
📉 The stock currently trades at a 36x TTM price-to-earnings multiple, pricing in strong execution of the commercial nuclear supercycle.
⚠️ Structural margin volatility within Government Operations remains a constant reality that limits upside surprises for defense contracting.
🔧 Realizing 20% EBITDA margins depends on scaling unproven commercial SMR production lines and navigating supply chain bottlenecks for specialty alloys.
📉 Insider selling has continued, including share sales by CEO Rex Geveden under a Rule 10b5-1 trading plan.
🏦 Hedge fund holders expanded to 65 in the second quarter, with Alkeon Capital Management holding the top position with 2.02 million shares.
📉 Short interest remains low at 4.42% of the public float, indicating limited bearish positioning against the stock.
Bullish Signals
Naval nuclear reactor monopoly provides sovereign defense moat.
Defense backlog doubled to $8.4 billion.
Selling medical unit for up to $800 million.
Targets $5.5B-$6B revenue by 2030.
EBITDA margins projected to expand to 20%.
Risk Factors
Stock fell from $241 highs to $130-$140 range.
Government Operations margins face structural volatility limits.
EBITDA expansion relies on unproven SMR scaling.
CEO Rex Geveden sold shares via Rule 10b5-1.
Market prices commercial nuclear at 36x TTM P/E.
Bullish Signals
BWX Technologies holds a virtual monopoly in manufacturing naval nuclear reactors for U.S. submarines and aircraft carriers, providing an irreplaceable sovereign defense moat.
Total backlog has doubled to $8.4 billion, representing roughly nine quarters of contracted run rate for the core defense business.
The company is selling a majority stake in its non-core medical isotope unit for up to $800 million to reallocate capital into high-return nuclear manufacturing assets.
Management targets annual revenues of $5.5 billion to $6 billion by 2030 with low double-digit compound organic growth.
Adjusted EBITDA margins are projected to expand from 17.5% to approximately 20% by the end of the decade.
Cumulative free cash flow generation is expected to exceed $2 billion through the end of the decade.
Hedge fund holders expanded to 65 in the second quarter, with Alkeon Capital Management leading institutional ownership.
Jim Cramer views the recent market pullback as a temporary dislocation rather than a structural flaw in the business model.
Risk Factors
The stock has endured a severe pullback from 52-week highs of over $241 down into the $130-$140 range, driven by a broader industrial selloff.
Structural margin volatility within Government Operations remains a constant reality that frequently limits upside surprises for defense contracting.
Realizing projected EBITDA margin expansion depends heavily on scaling unproven commercial SMR production lines while navigating ongoing supply chain bottlenecks for military-grade specialty alloys.
Insider selling has continued, including share sales by CEO Rex Geveden under a Rule 10b5-1 trading plan.
The market is pricing in strong execution of the commercial nuclear power supercycle at a 36x TTM price-to-earnings multiple, leaving little margin for error.
BWX Technologies (NYSE: BWXT) significantly raised its long-term growth outlook at its 2026 Investor Day, targeting total revenue between $5.5 billion and $6 billion by 2030. The company projects adjusted EBITDA of $1.1 billion to $1.2 billion and free cash flow of $525 million to $575 million for the same period, with operating margins expected to expand from 17.5% in 2026 to approximately 20% by 2030.
The company's order backlog has more than doubled to $8.4 billion since early 2024, representing roughly nine quarters of work at the current run rate. CEO Rex Geveden highlighted a diversified portfolio spanning commercial nuclear projects, naval propulsion systems, advanced reactors, and special materials contracts, positioning BWXT as a global industrial champion with manufacturing sites across North America and Europe.
Growth is driven by high-teens annual revenue growth in Commercial Operations through 2030 and strong performance in Government Operations. Key drivers include the sale of a majority interest in BWXT Medical for up to $800 million, which provides capital for organic investment and acquisitions, alongside major contracts for depleted uranium, enrichment initiatives, and reactor components like steam generators and fuel assemblies.
Management reaffirmed 2026 guidance with specific targets for Government Operations revenue growth and outlined a framework for Commercial Operations following the divestiture of its medical business. The company maintains disciplined capital allocation, planning expenditures at 5% to 6% of revenue, while leveraging automation and digital tools to improve manufacturing throughput and support energy security needs.
📈 BWXT raised 2030 revenue targets to $5.5B-$6B with adjusted EBITDA of $1.1B-$1.2B.
📊 Backlog surged to $8.4 billion, providing nine quarters of work at current run rates.
💰 Margins expected to expand from 17.5% in 2026 to ~20% by 2030 as operations scale.
🏭 Commercial Operations projected for high-teens annual revenue growth through 2030 via nuclear component supply.
🛡️ Government Operations backlog nears $7 billion, with naval propulsion at ~70% of segment revenue.
📈 BWXT raised its long-term targets to $5.5B-$6B revenue by 2030, with adjusted EBITDA of $1.1B-$1.2B and free cash flow of $525M-$575M.
📊 The company's backlog surged to $8.4 billion, more than doubling from the prior Investor Day and providing nine quarters of work at current run rates.
💰 CEO Rex Geveden expects margins to expand from 17.5% in 2026 to approximately 20% by 2030 as commercial operations scale.
🏭 Commercial Operations is projected to deliver high-teens annual revenue growth through 2030, driven by expanded nuclear component supply.
🛡️ Government Operations accounts for nearly $7 billion of total backlog, with naval propulsion representing about 70% of segment revenue.
💼 BWXT announced the sale of a majority interest in BWXT Medical for up to $800 million while retaining a ~20% stake.
🔋 The company secured major contracts including a $1.63B deal for depleted uranium and a $1.5B contract for centrifuge technology scaling.
⚙️ BWXT delivered over 325 commercial steam generators and has 60 more in backlog, expanding its Cambridge, Ontario facility by 40%.
🌍 The company is pursuing opportunities in the U.S., Europe, and Canada, including work on AP1000 deployment in Bulgaria and SMR projects.
🚀 Naval nuclear propulsion business is expected to grow at a 4% to 6% compound annual rate based on existing shipbuilding plans.
🔬 BWXT completed fuel delivery for Project Pele and is preparing the reactor for shipment and fueling at Idaho National Laboratory.
💸 CFO Mike Fitzgerald stated the company expects to generate more than $2 billion in cumulative free cash flow from 2026 through 2030.
📉 Capital expenditures are planned to remain in a range of 5% to 6% of revenue, with disciplined allocation for growth and maintenance.
🏢 BWXT operates 16 major manufacturing sites across North America and Europe, utilizing 5 million square feet of nuclear-qualified space.
👥 The company employs approximately 11,400 people globally to support its diverse portfolio of government and commercial nuclear solutions.
Bullish Signals
Raised long-term revenue target to $5.5B-$6B by 2030.
Backlog more than doubled to $8.4 billion.
Margins expected to expand from 17.5% to 20% by 2030.
Commercial Operations projected for high-teens annual revenue growth.
Secured $1.63B depleted uranium and $1.5B centrifuge contracts.
Bullish Signals
BWXT raised its long-term revenue target to $5.5B-$6B by 2030, representing low-double-digit annual growth from the 2026 baseline.
The company's backlog more than doubled to $8.4 billion, providing roughly nine quarters of work at the current run rate.
Margins are expected to expand from 17.5% in 2026 to approximately 20% by 2030 as commercial operations scale.
Commercial Operations is projected to deliver high-teens annual revenue growth through 2030, driven by expanded nuclear component supply.
BWXT announced the sale of a majority interest in BWXT Medical for up to $800 million, providing significant capital for organic investment and acquisitions.
The company secured major contracts including a $1.63B deal for depleted uranium and a $1.5B contract for centrifuge technology scaling.
BWXT delivered over 325 commercial steam generators and has 60 more in backlog, expanding its Cambridge, Ontario facility by 40%.
Naval nuclear propulsion business is expected to grow at a 4% to 6% compound annual rate based on existing shipbuilding plans.
BWXT expects to generate more than $2 billion in cumulative free cash flow from 2026 through 2030, supporting shareholder returns.
The company reaffirmed its 2026 guidance and provided an initial 2027 framework calling for high-single-digit revenue and adjusted EBITDA growth.
BWX Technologies (BWXT) closed at USD 147.12 on September 21, 2026, trading just USD 2.79 above its 52-week low of USD 144.33. The stock's market capitalization stood at USD 13.51 billion with a volume of 962,856 shares on the NYSE. This price action places the security near the bottom of its annual trading range, which spans from USD 144.33 to a high of USD 241.82.
Despite the low closing price, the company maintains a substantial financial base with fiscal year 2025 revenue reaching USD 3.20 billion and a net income margin of 10.11 percent. Analysts maintain a consensus price target of USD 207.50 for the third quarter of 2026, implying significant upside potential relative to the current market price.
The stock recently gained momentum following news of a new nuclear contract, though it continues to trade at a reported price-to-earnings ratio of 37.71. Investors are currently weighing this positive operational development against the company's depressed valuation and execution risks inherent in trading near its yearly floor.
📉 BWXT closed at $147.12, just $2.79 above its 52-week low.
💰 FY2025 revenue reached $3.20 billion with a $13.51B market cap.
📈 Analysts see $207.50 target price, implying ~41% upside potential.
⚙️ Stock rose after securing a new nuclear contract for operations.
📊 FY2025 net income margin hit 10.11% with a P/E of 37.71.
📉 BWX Technologies closed at USD 147.12 on September 21, 2026, trading only USD 2.79 above its 52-week low of USD 144.33.
💰 The company reported a market capitalization of USD 13.51 billion with fiscal year 2025 revenue reaching USD 3.20 billion.
📈 Analysts maintain a consensus price target of USD 207.50, representing approximately 41% upside from the current closing price.
⚙️ The stock recently gained value following the announcement of a new nuclear contract within its business operations.
🏭 BWXT operates in the Industrials sector with a specific focus on Aerospace and Defense industries.
📊 The company reported a net income margin of 10.11 percent for fiscal year 2025, indicating solid profitability.
🔍 The stock trades at a price-to-earnings ratio of 37.71 as of the latest reporting period.
Bullish Signals
Nuclear contract provides operational catalyst.
Analysts target $207.50 vs $147.12 price.
Risk Factors
Stock closed $2.79 above 52-week low of $144.33.
Trades $94.70 below 52-week high of $241.82.
Bullish Signals
BWX Technologies recently gained on a new nuclear contract, providing a positive operational catalyst for the company.
Analysts maintain a consensus price target of USD 207.50, which is significantly higher than the current trading price of USD 147.12.
Risk Factors
The stock closed at USD 147.12, which is only USD 2.79 above its 52-week low of USD 144.33, indicating depressed market sentiment.
BWXT trades USD 94.70 below its 52-week high of USD 241.82, suggesting the stock is near the bottom of its annual trading range.
BWX Technologies (BWXT) secured a USD 4 million design contract from the National Nuclear Security Administration for a lithium processing facility at the Y-12 National Security Complex. This award represents an early-stage engineering milestone where BWXT is tasked with developing the conceptual design for the first module, distinguishing it from a full construction contract and establishing a measurable starting point for potential future opportunities.
Financially, the company reported strong second-quarter 2026 results with revenue reaching USD 901.62 million, marking an 18.0 percent increase year-over-year. BWXT also beat analyst consensus on earnings per share, reporting USD 1.07 compared to the expected USD 1.04, demonstrating solid operating execution despite the stock trading near the lower end of its 52-week range.
Looking ahead, BWXT has set fiscal-year 2026 earnings guidance between USD 4.70 and USD 4.80 per share, which is slightly below the cited analyst forecast of USD 4.75. With a market capitalization of USD 13.51 billion, the company's key reference points remain its ability to convert design awards into construction contracts and sustain its double-digit sales growth trajectory.
💰 EPS beat consensus at $1.07 vs $1.04 in Q2 2026.
🎯 FY2026 guidance set at $4.70-$4.80, slightly below analyst forecast.
📉 Stock closed at $147.12 near lower end of 52-week range.
🏗️ BWXT received a USD 4 million initial design contract from the National Nuclear Security Administration for a lithium processing facility at the Y-12 National Security Complex.
📈 The company reported second-quarter 2026 revenue of USD 901.62 million, representing an 18.0 percent increase from the prior year.
💰 BWXT achieved an earnings per share beat of USD 1.07 versus the analyst consensus of USD 1.04 in Q2 2026.
🎯 The company set fiscal-year 2026 earnings guidance at USD 4.70 to USD 4.80 per share, slightly below the cited analyst forecast of USD 4.75.
📉 BWXT stock closed at USD 147.12 on September 21, 2026, trading near the lower end of its 52-week range of USD 144.33 to USD 241.82.
💼 The company's market capitalization stood at USD 13.51 billion as of September 21, 2026.
🔬 This contract award serves as an early-stage engineering milestone rather than a full construction contract for the lithium facility.
Bullish Signals
Secured USD 4M design contract for lithium facility at Y-12.
Q2 2026 revenue rose 18% YoY to USD 901.62M.
Beat EPS expectations with USD 1.07 vs USD 1.04.
Risk Factors
FY2026 guidance of $4.70-$4.80 misses analyst consensus of $4.75.
Bullish Signals
BWXT secured a USD 4 million design contract from the National Nuclear Security Administration to develop the conceptual design for a lithium processing facility at Y-12.
The company reported second-quarter 2026 revenue of USD 901.62 million, reflecting an 18.0 percent year-over-year increase.
BWXT beat analyst earnings per share expectations with a result of USD 1.07 compared to the consensus of USD 1.04.
Risk Factors
BWXT's fiscal-year 2026 earnings guidance of USD 4.70 to USD 4.80 per share is slightly below the cited analyst forecast of USD 4.75.
BWX Technologies, Inc. (BWXT) is currently trading at $145.66 as of September 17, 2026, presenting a significant upside potential according to Wall Street consensus. Analysts maintain a 'Buy' rating with a median price target of $230.00, suggesting approximately 57.9% growth from current levels. The stock exhibits strong fundamental metrics, including a high return on equity of 28.29% and a solid profit margin of 10.11%, which outperform sector averages.
Despite the bullish analyst consensus, technical indicators show short-term weakness as the price trades below its 50-day average of $165.39 and 200-day moving average of $191.93. Revenue growth forecasts are robust, with analysts predicting a 19% increase for the current year followed by 10% growth next year. However, insider activity presents a mixed signal, with insiders having sold approximately $14.4 million in stock while reporting no significant purchases.
Long-term simulations project varied outcomes for BWXT investors over the next decade. A Monte Carlo simulation suggests a base case price near $218 by 2030, representing a 1.5x return from current levels, though downside scenarios could see prices drop to around $96.73. Historical data indicates that a $10,000 investment in BWXT since September 2016 has outperformed the S&P 500 benchmark, growing to approximately $37,893 compared to $35,333 for the index.
The article concludes with standard financial disclaimers noting that all trade setups and performance metrics are hypothetical and simulated. CleaRank emphasizes that past volatility does not predict future returns and advises consulting a qualified financial advisor before making investment decisions based on these AI-generated signals.
📈 BWXT trades at $145.66 with a $230 consensus target (57.9% upside).
💰 Strong financial health: 28.29% ROE and 10.11% profit margin.
📊 Forecasted revenue growth of 19% this year and 10% next year.
📉 Stock trades below $165.39 (50-day) and $191.93 (200-day) averages.
💸 Insiders recently sold approximately $14.4 million in BWXT stock.
📈 BWXT trades at $145.66 with a Wall Street consensus price target of $230.00, indicating 57.9% upside potential.
💰 The company demonstrates strong financial health with a return on equity of 28.29% and a profit margin of 10.11%, outperforming sector averages.
📊 Analysts forecast current year revenue growth of 19% and next year growth of 10%, supported by strong quarterly estimates.
📉 Technical indicators show weakness as the stock trades below its 50-day average of $165.39 and 200-day moving average of $191.93.
💸 Insider selling activity is notable, with insiders having sold approximately $14.4 million worth of BWXT stock recently.
🔮 Monte Carlo simulations project a base case price near $218 by 2030, assuming no dividends are reinvested.
📉 Historical backtests show a $10,000 investment in BWXT since September 2016 grew to $37,893, outperforming the S&P 500.
⚠️ The article notes that all performance metrics and trade setups presented are hypothetical and simulated for educational purposes.
Bullish Signals
ROE is 28.29% with profit margin of 10.11%.
Revenue forecast grows 19% this year and 10% next.
Wall Street consensus Buy rating targets $230.00.
Stock outperformed S&P 500 since Sept 2016.
Risk Factors
Stock trades below 50-day and 200-day moving averages.
Insiders sold $14.4M with no significant purchases.
Bullish Signals
BWXT demonstrates a high return on equity of 28.29% and a solid profit margin of 10.11%, significantly outperforming sector averages.
Analysts forecast robust revenue growth of 19% for the current year and 10% for next year, supported by strong quarterly estimates.
Wall Street consensus maintains a 'Buy' rating with a median price target of $230.00, indicating substantial upside potential from current levels.
Historical performance since September 2016 shows the stock outperforming the S&P 500 benchmark, growing a $10,000 investment to approximately $37,893.
Risk Factors
The stock is currently trading below its 50-day and 200-day moving averages, indicating short-term technical weakness and potential resistance.
Insider selling activity is concerning, with insiders having sold approximately $14.4 million worth of BWXT stock while no significant purchases were reported.
BWX Technologies (BWXT) is receiving renewed attention from Wall Street analysts and investors as a key beneficiary of the nuclear renaissance. Jefferies initiated coverage with a Buy rating and an $181 price target, citing the company's strong position in nuclear components and U.S. Navy contracts. Social media sentiment highlights BWXT's operating leverage and expected earnings per share growth through 2030, positioning it as a steady defensive play within the expanding nuclear supply chain.
The company reported robust financial performance for the second quarter of 2026, with revenues reaching $901.6 million, representing an 18.01% year-over-year increase. Analysts have established a median price target of $230.00 over the last six months, with specific targets ranging from $200 to $255 from firms including Deutsche Bank, Truist Securities, and Wells Fargo. This consensus reflects confidence in BWXT's technical barriers and manufacturing scale within small modular reactor (SMR) development and fuel cycle activities.
Institutional investor activity shows a mixed but generally positive trend regarding portfolio positioning. Major institutions like JPMorgan Chase and Select Equity Group significantly increased their holdings in Q2 2026, adding hundreds of millions of dollars to their portfolios. Conversely, some hedge funds completely exited their positions, while insider trading data reveals that CEO Rex D. Geveden has sold shares recently, though no purchases were recorded by insiders in the past six months.
📈 Jefferies initiates Buy on BWXT with $181 price target.
💰 Q2 2026 revenues surge 18% to $901.6 million.
🎯 Median analyst price target stands at $230.00.
🏛️ Company holds $8.4 billion backlog in nuclear supply chain.
📉 CEO sold 10,000 shares for $1.7 million recently.
📈 Jefferies initiated a Buy rating on BWXT with an $181 price target, highlighting the company's strong position in nuclear components and U.S. Navy contracts.
💰 BWX Technologies reported Q2 2026 revenues of $901.6 million, marking an 18.01% increase compared to the same period in the prior year.
🎯 Analysts have set a median price target of $230.00 for BWXT, with Deutsche Bank offering a high target of $255.00 and Wells Fargo at $200.00.
🏛️ The company maintains an $8.4 billion backlog, reinforcing its role as a core beneficiary in the expanding nuclear supply chain.
📉 CEO Rex D. Geveden sold 10,000 shares for approximately $1.7 million over the past six months with no insider purchases recorded during that period.
🏦 JPMorgan Chase & Co. added 2.65 million shares to its portfolio in Q2 2026, representing an estimated investment of $516.6 million.
⚙️ Investors view BWXT as a technical leader with manufacturing scale advantages specifically in SMR development and fuel cycle activities.
📊 Institutional ownership saw net additions from major firms like Select Equity Group (+134.6%) and First Trust Advisors (+49.2%) in the most recent quarter.
💼 The company received $143.25 million in award payments over the last year, with enriched uranium conversion services accounting for the majority of that value.
Bullish Signals
Jefferies initiated Buy with $181 target citing strong nuclear positioning.
Q2 2026 revenues surged 18.01% YoY to $901.6 million.
Company holds substantial $8.4 billion backlog validating market position.
Deutsche Bank set high $255 target on technical barriers.
Simply Wall St analysis suggests BWX Technologies (BWXT) stock is currently overvalued, trading at a premium to its intrinsic value based on Discounted Cash Flow (DCF) and earnings multiples. The DCF model estimates an intrinsic value of approximately $132 per share, while the current price implies a valuation roughly 22.1% above this level. Additionally, the company trades at a P/E ratio of 41.7x, which is significantly higher than both the peer average of 23.5x and the broader Aerospace and Defense industry average of 36.0x.
The article highlights that while BWXT has delivered strong share gains over the past five years with a record $6 billion backlog up 70% year-over-year, these metrics may already be priced in. The recent selection of the BWXT Advanced Nuclear Reactor for the U.S. Army's Janus program provides long-term contract visibility and supports optimism, but execution risks regarding regulatory approvals and construction remain key considerations for investors underwriting future cash flows.
Ultimately, the valuation checks lean towards a '1 out of 6' score, indicating the stock does not screen as a clear value opportunity at current levels. The core question remains whether BWXT can convert its expanding contract pipeline and reactor projects into sustained cash flows and earnings growth sufficient to justify the existing premium, or if expectations will cool and the valuation settles closer to intrinsic value.
📉 Simply Wall St models BWXT as 22.1% overvalued at $132 intrinsic value.
💰 BWXT trades at a 41.7x P/E ratio, significantly above peer averages.
🚀 BWXT secures Janus program reactor selection for enhanced long-term contract visibility.
📈 BWXT reports record $6 billion backlog with 70% year-over-year growth.
⚠️ BWXT faces execution risks from regulatory approvals and construction timelines.
📉 Simply Wall St analysis indicates BWX Technologies is overvalued by approximately 22.1% based on a Discounted Cash Flow (DCF) model projecting an intrinsic value of $132 per share.
💰 The company trades at a P/E ratio of 41.7x, which exceeds the peer average of 23.5x and the industry average of 36.0x, suggesting a sizeable premium to earnings.
🚀 BWXT secured a major win with the selection of its Advanced Nuclear Reactor for the U.S. Army's Janus program, enhancing long-term contract visibility.
📈 The company reports a record backlog of $6 billion, representing a 70% year-over-year increase driven by multi-year defense contracts.
⚠️ Investors face execution risks related to regulatory approvals and construction timelines for advanced nuclear reactor projects.
🏭 BWXT operates in the Aerospace and Defense industry with manufacturing capabilities in the United States, Canada, and internationally.
Bullish Signals
U.S. Army selected Advanced Nuclear Reactor for Janus program.
Record backlog hit $6B, up 70% year-over-year.
Risk Factors
Stock overvalued by 22.1% vs intrinsic value.
P/E ratio of 41.7x exceeds peer average.
Bullish Signals
The U.S. Army selected the BWXT Advanced Nuclear Reactor for the Janus program, providing long-term contract visibility and supporting future revenue growth.
The company achieved a record backlog of $6 billion, which is up 70% year-over-year, driven by multi-year defense contracts and an expanding opportunity pipeline.
Risk Factors
Valuation analysis suggests the stock is overvalued by approximately 22.1% relative to its intrinsic value estimate derived from discounted cash flow projections.
The current P/E ratio of 41.7x carries a significant premium compared to the peer average of 23.5x and the industry average of 36.0x.
We use cookies to run the site and, only if you allow it, for live chat, analytics, personalization and ad measurement.
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Offer a live chat with our team (Enuchat, optional)
Measure audience engagement and site statistics to understand how our services are used (Google Analytics, optional)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
Measure how our ads on Facebook and Instagram perform, including whether a visit leads to a confirmed sign-up, matched to your Facebook or Instagram account using hashed contact details you enter (Meta Pixel, optional)
Optional cookies are only set if you allow them. You can accept all, reject all or choose per category, and change your choice at any time via the "Manage Cookies" link in the footer. Google and Meta may process this data in the USA. More in our Privacy Policy.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Functional cookies
Show the live chat button so you can message our team. The Enuchat chat widget stores a visitor ID in your browser and sends your chat messages to Enuchat. When this is off, the chat is not loaded.
Cookie
Purpose
Duration
enuchat_visitor_id
Keeps your chat conversation linked to this browser (Enuchat, browser storage)
Until you clear it or turn this off
Analytics cookies
Help us understand how visitors use our website with Google Analytics, provided by Google LLC. Google receives pages visited, device data and an IP address, and may process them in the USA. If you also allow marketing cookies, the Google tag can detect contact details you enter or see on our pages, such as your email address, phone number, name or address, hash them before sending and pass them to Google so it can match your visits to a Google account for measuring our ads. Hashed details are still personal data. See how Google uses information from sites that use its services.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
1 year
Marketing cookies
Let Meta (Facebook and Instagram) measure how our ads perform, using the Meta Pixel. Meta Platforms Ireland Ltd. receives the pages you visit and, when you confirm the email address of a new account, a "completed registration" event, together with browser identifiers and your IP address. Meta's automatic advanced matching also reads contact details you type into forms on our site, such as your email address or name, hashes them in your browser and sends them with these events so Meta can match them to a Facebook or Instagram account. Hashed details are still personal data. These events are sent from your browser and may also be forwarded to Meta through Meta's Conversions API Gateway. Our own server also sends page visits and completed-registration events directly to Meta's Conversions API, with your IP address, browser user agent and Meta browser identifiers, so Meta can count it once. To help Meta match these visits, your browser and our server also send a random visitor ID from our own cookie and, if you are signed in, your account ID, your confirmed email address and the name, city, postal code and country saved in your profile, all hashed first. We and Meta are joint controllers for collecting and sending this data, and Meta's further use, which may include processing in the USA, is described in the Meta Privacy Policy. When this is off, the Meta Pixel is not loaded and no page visit or registration event is sent to Meta. Together with analytics cookies, this choice also lets Google receive hashed contact details, as described under Analytics cookies.
Cookie
Purpose
Duration
_fbp
Identifies browsers for Meta ad measurement (Meta Pixel)
3 months
_fbc
Stores the Meta ad click that brought you here (Meta Pixel)
3 months
_bes_meid
Random visitor ID, sent to Meta only hashed, so your visits can be matched (Meta Pixel and Conversions API)